摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-iodo-4-isopropyl-thiazol-2-ylamine | 1158211-86-9

中文名称
——
中文别名
——
英文名称
5-iodo-4-isopropyl-thiazol-2-ylamine
英文别名
5-iodo-4-propan-2-yl-1,3-thiazol-2-amine
5-iodo-4-isopropyl-thiazol-2-ylamine化学式
CAS
1158211-86-9
化学式
C6H9IN2S
mdl
——
分子量
268.121
InChiKey
HVCAQYVJUZUTFV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    67.2
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-[4-(cyclopropylsulfonyl)phenyl]-3-(tetrahydro-2H-pyran-4-yl)propionic acid5-iodo-4-isopropyl-thiazol-2-ylamine 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 作用下, 以 二氯甲烷 为溶剂, 以62%的产率得到2-(4-(cyclopropylsulfonyl)phenyl)-N-(5-iodo-4-isopropylthiazol-2-yl)-3-(tetrahydro-2H-pyran-4-yl)propanamide
    参考文献:
    名称:
    Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators
    摘要:
    A series of N-thiazole substituted arylacetamides were designed on the basis of metabolic mechanism of the aminothiazole fragment as glucokinase (GK) activators for the treatment of type 2 diabetes. Instead of introducing a substituent to block the metabolic sensitive C-5 position on the thiazole core directly, a wide variety of C-4 or both C-4 and C-5 substitutions were explored. Compound R-9k bearing an iso-propyl group as the C-4 substituent was found possessing the highest GK activation potency with an EC50 of 0.026 mu M. This compound significantly increased both glucose uptake and glycogen synthesis in rat primary cultured hepatocytes. Moreover, single oral administration of compound R-9k exerted significant reduction of blood glucose levels in both ICR and ob/ob mice. These promising results indicated that compound R-9k is a potent orally active GK activator, and is warranted for further investigation as a new antidiabetic treatment. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2010.04.038
  • 作为产物:
    参考文献:
    名称:
    NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES
    摘要:
    式(I)的化合物以及其药用可接受的盐和酯,其中R1至R3具有权利要求1中给定的含义,并可用于制成药物组合物。
    公开号:
    US20090143448A1
点击查看最新优质反应信息

文献信息

  • Aminothiazoles as FBPase inhibitors for diabetes
    申请人:Hoffman-La Roche Inc.
    公开号:US07973051B2
    公开(公告)日:2011-07-05
    Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R3 have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.
    化合物(I)的公式,以及其药学上可接受的盐和酯,其中R1到R3具有权利要求1中给出的意义,并且可以用于制成药物组成物的形式。
  • AMINOTHIAZOLE DERIVATIVES
    申请人:F. Hoffmann-La Roche AG
    公开号:EP2227468A1
    公开(公告)日:2010-09-15
  • US7973051B2
    申请人:——
    公开号:US7973051B2
    公开(公告)日:2011-07-05
  • [EN] AMINOTHIAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'AMINOTHIAZOLE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2009068467A1
    公开(公告)日:2009-06-04
    Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R3 have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.
查看更多